argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2015-04-23 07:46 |
arGEN-X announces publication on therapeutic potential of antibody ARGX-115 in …
|
English | 39.8 KB | ||
| 2015-04-15 15:08 | English | 4.0 MB | |||
| 2015-04-15 15:05 | English | 502.4 KB | |||
| 2015-04-14 08:31 |
arGEN-x N.V. Announces Changes to the Board of Directors
|
English | 25.7 KB | ||
| 2015-04-08 07:31 |
arGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111 in Patients with M…
|
English | 18.0 KB | ||
| 2015-04-01 07:30 |
arGEN-X announces Annual General Meeting of Shareholders 13 May 2015
|
English | 29.1 KB | ||
| 2015-03-18 19:47 |
arGEN-X Reports Fourth Quarter Business Update And Full Year 2014 Financial Res…
|
English | 190.4 KB | ||
| 2015-03-13 08:44 |
arGEN-X to Present at 22nd Annual BioCentury Future Leaders in the Biotech Indu…
|
English | 19.2 KB | ||
| 2015-03-11 08:49 |
arGEN-X to Host Conference Call & Webcast to Report Fourth Quarter Business Upd…
|
English | 32.3 KB | ||
| 2015-03-04 07:46 |
arGEN-X EXPANDS PRECLINICAL PIPELINE WITH ARGX-115: A NOVEL SIMPLE ANTIBODY(TM)…
|
English | 33.1 KB | ||
| 2015-02-18 07:25 |
Lonza and arGEN-X Announce a Multi-product GS Xceed(TM) License Agreement for T…
|
English | 24.6 KB | ||
| 2015-01-12 08:32 |
arGEN-X Launches Innovative Access Program
|
English | 93.0 KB | ||
| 2014-12-11 07:11 |
arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire
|
English | 90.5 KB | ||
| 2014-12-09 08:20 |
arGEN-X Reports Preclinical Data on ARGX-110 in Chronic Myelogenous Leukemia Mo…
|
English | 87.0 KB | ||
| 2014-11-14 08:09 |
arGEN-X - Third Quarter Business Update
|
English | 502.4 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
